Garrido, PedroAlexandre, Maria InêsTravassos, Ana RitaFilipe, Paulo2021-09-302021-09-302020Dermatol Ther. 2020 Nov;33(6):e141601396-0296http://hdl.handle.net/10451/49720© 2020 Wiley Periodicals LLC.Bullous pemphigoid (BP) is the most common autoimmune blistering disease. High potency topical and/or systemic corticosteroids as well as immunosuppressants are the current mainstay of treatment. However, long-term steroid therapy and systemic immunosuppression may result in significant morbidity and mortality. Contribution of IgE to BP pathogenesis remains under investigation, but increasing evidence supports a pathogenic significance. Omalizumab is a recombinant humanized monoclonal anti-IgE antibody that has recently emerged as a novel promising treatment alternative for BP.engjournal article10.1111/dth.141601529-8019